• District of Columbia: Chip Kahn, president and CEO of the Federation of American Hospitals (FAH), will retire from his position at the end of 2025. Kahn has been FAH's CEO for 24 years and is the organization's third CEO since its founding in 1966. During his time with the organization, Kahn helped create the Hospital Quality Alliance and had a key role with the National Quality Forum, which developed a national strategy for quality improvement. "What an honor to have an opportunity for a quarter century — and during a consequential period of health policy making — to be the play caller for this important hospital sector. Much has been accomplished," Kahn said. "Now it is time for a career turn to work on policy from another vantage point. I look forward to engaging in efforts to foster healthcare affordability, coverage and quality improvement." According to Becker's Hospital Review, FAH's board has hired consulting firm Korn Ferry to assist in the search for Kahn's successor. (Bean, Becker's Hospital Review, 6/6)
• Illinois: Judge Matthew Kennelly of the U.S. District Court for the Northern District of Illinois has denied motions to dismiss two lawsuits against Claritev, a data analytics firm that was formerly known as MultiPlan, and several insurers. According to Modern Healthcare, the lawsuits allege that Claritev worked with insurers to reduce payments for out-of-network providers, which violated state and federal antitrust laws under the Sherman Act. In January, Claritev filed to dismiss the complaints, arguing that the market for out-of-network services among insurers is nonexistent. In response to Kennelly's decision, Claritev said that it remains "confident in the strength of [its] legal position and look forward to presenting the facts as the case moves forward" and "will vigorously defend ourselves through the legal process while remaining focused on delivering value to our customers and the broader healthcare ecosystem." (DeSilva, Modern Healthcare, 6/3)
• Maryland: Four states — California, Massachusetts, New Jersey, and New York — have filed a petition asking FDA to lift restrictions on the abortion medication mifepristone. In the petition, the states requested FDA completely lift the Risk Evaluation and Mitigation Strategy (REMS) framework on mifepristone, saying that "given mifepristone's well-established, 25-year safety record, FDA's current restrictions on mifepristone are no longer justified by science or law." Citing new studies, the states argued that "mifepristone's safety has remained stable even as its restrictions have been lessened" and that keeping the restrictions "cannot be squared with the FDA's lack of REMS programs on drugs that have significantly more risks than mifepristone." According to the New York Times, FDA is required to respond to the petition within 180 days by granting or denying the request or asking for more time to consider it. The agency must document its position in its response, which could be useful for lawsuits if the petition is denied. Separately, FDA has said it plans to review the safety of mifepristone after a conservative organization released a report saying that mifepristone is more dangerous than many studies show. However, medical experts argue that the report has several flaws, including a lack of peer review and sources for the insurance claims data it reviewed. (Belluck, New York Times, 6/5)

As we have seen across the past few years, the ramifications of the Dobbs v. Jackson  decision are far-reaching. Not only do leaders have to navigate consequences for patients themselves, but they must also balance the needs of the clinical workforce. Access the expert insight to learn a few ways that leaders of provider organizations should address the most pressing impacts of the ruling on their workforce right now.